GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Gross-Profit-to-Asset %

ARCA biopharma (FRA:HQ10) Gross-Profit-to-Asset % : 0.00% (As of Jun. 2024)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ARCA biopharma's annualized Gross Profit for the quarter that ended in Jun. 2024 was €0.00 Mil. ARCA biopharma's average Total Assets over the quarter that ended in Jun. 2024 was €32.61 Mil. Therefore, ARCA biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 was 0.00%.


ARCA biopharma Gross-Profit-to-Asset % Historical Data

The historical data trend for ARCA biopharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Gross-Profit-to-Asset % Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARCA biopharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, ARCA biopharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Gross-Profit-to-Asset % falls into.



ARCA biopharma Gross-Profit-to-Asset % Calculation

ARCA biopharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (40.672+34.719)/ 2 )
=0/37.6955
=0.00 %

ARCA biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Jun. 2024 )/( (Total Assets (Q: Mar. 2024 )+Total Assets (Q: Jun. 2024 ))/ count )
=0/( (33.77+31.441)/ 2 )
=0/32.6055
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


ARCA biopharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines